RT Journal Article
SR Electronic
T1 Serum autotaxin levels in chronic disease and acute exacerbation of fibrosing interstitial lung disease
JF ERJ Open Research
JO erjor
FD European Respiratory Society
SP 00683-2021
DO 10.1183/23120541.00683-2021
VO 8
IS 2
A1 Takuma Isshiki
A1 Hiroshige Shimizu
A1 Susumu Sakamoto
A1 Akira Yamasaki
A1 Shion Miyoshi
A1 Yasuhiko Nakamura
A1 Sakae Homma
A1 Kazuma Kishi
YR 2022
UL http://openres.ersjournals.com/content/8/2/00683-2021.abstract
AB Background Autotaxin (ATX) is an ecto-enzyme that catalyses the hydrolysis of lysophospholipids to the lipid mediator lysophosphatidic acid (LPA). LPA/ATX signalling has emerged as a new therapeutic target for pulmonary fibrosis; however, the serum levels and dynamics of ATX during the clinical course of fibrosing interstitial lung disease (ILD) remain unknown. This study sought to examine the serum ATX levels in fibrosing ILD in the chronic phase and in acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF). We aimed to elucidate the association between serum ATX level and clinical characteristics including disease progression and prognosis.Methods In total, 119 patients with fibrosing ILD and 38 healthy volunteers as controls were enrolled in the study and their serum ATX activity was analysed. We also included six male patients with AE-IPF in order to analyse the changes in serum ATX at the onset of AE-IPF.Results Patients with fibrosing ILD showed significantly higher serum ATX levels compared with healthy controls in both sexes. Per cent change in forced vital capacity after 1 year correlated with serum ATX levels in female patients. High serum ATX levels (>0.721 mg· L−1) were associated with worse outcome in survival curve and multivariate analysis of male patients. Serum ATX activity decreased after the onset of AE-IPF.Conclusion Serum ATX levels were significantly higher in patients with fibrosing ILD compared with healthy controls, and this was associated with disease progression and outcome. This suggests the potential of serum ATX as a promising biomarker for the treatment of fibrosing ILD.Serum ATX levels are higher in fibrosing ILD than in healthy controls; this is associated with disease progression and outcome. Serum ATX levels decrease at the onset of AE-IPF. https://bit.ly/3hLR9jN